Stay updated on Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe Taoyuan District listing was replaced with Taoyuan, reflecting a city-level designation with the same postal code 33305. This aligns the location with the actual site and improves accuracy for recruitment and contact information.SummaryDifference0.0%

- Check13 days agoChange DetectedThe page’s displayed software/site revision indicator has been updated from v3.5.0 to v3.5.3. This represents a maintenance/frontend version change rather than an update to the clinical trial information presented.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedSite listing updated from Napoli, Italy, 80131 to Naples, Italy, 80131. Page revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision history updated to include v3.4.3 and remove v3.4.2.SummaryDifference0.0%

- Check85 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2; this is a minor maintenance update with no visible changes to study data or navigation, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check92 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.